Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Post by MrMugsyon May 09, 2022 11:52am
183 Views
Post# 34667172

Endo ... watching just for fun

Endo ... watching just for funIt is for no other reason than for "fun" that we watch the demise of Paladin's acquirer - Endo.
Also ... to see if GUD makes any kind of play for their 69 Canadian drugs.  The price is likely not right - but - fun to watch anyway.

It was obvious back then that using debt to run a series of acquisitions was not a good idea for the long-term.

The market cap of Endo is now $332M and debt totals approximately $8 Billion ... Seeking Alpha may have been on to something in their comments back in August 2021 ...


  • With a weak balance sheet, lingering opioid lawsuits and the upcoming threat of a generic vasopressin competitor, the likelihood of a bankruptcy announcement in the coming months is high.

Endo has been fighting hard - but for how long?  The opioid crisis will surely do them in.  Did Seeking Alpha make the right call?  Will see.


With the recent announcement of the hiring of a restructuring adviser, I believe Endo is likely on its last legs and will follow the path of its peer, Mallinckrodt (MNK), i.e. into Chapter 11 bankruptcy filing.



  •  
<< Previous
Bullboard Posts
Next >>